Scientists Share Nobel Prize for Discoveries That Changed Pain Research
Title: Scientists Share Nobel Prize for Discoveries That Changed Pain ResearchCategory: Health NewsCreated: 10/4/2021 12:00:00 AMLast Editorial Review: 10/5/2021 12:00:00 AM
ConclusionThis study was the preparatory phase for a future trial on a method to stimulate setting specific goals. The future trial would provide a thorough understanding of the quality of person-defined goals.
Condition: Chronic Pain Interventions: Drug: LY3526318; Drug: Placebo Sponsor: Eli Lilly and Company Not yet recruiting
Conditions: Chronic Low-back Pain; Fibromyalgia Interventions: Drug: Propranolol Hydrochloride; Drug: Placebo; Behavioral: Reactivation procedure; Behavioral: Pain neuroscience education Sponsor: Université de Sherbrooke Not yet recruiting
Condition: Neck Pain Interventions: Other: Exercise; Other: Manual Therapy + Exercise Sponsor: Universitat Internacional de Catalunya Recruiting
CONCLUSION: chronic administration of quercetin showed decreased oxidative/nitrosative stress in the liver, kidney, adrenal, and heart tissues. Quercetin plus naloxone decreased oxidative stress in the heart and adrenal tissues, but adverse effects on the brain cortex and hepatic function. Single-dose quercetin reduced cardiac oxidative stress.PMID:34666816 | DOI:10.1186/s40360-021-00532-8
CONCLUSION: In patients already treated with an endovascular revascularization of the SMA or celiac trunk (CT), open surgical repair through a single retrograde aorto-mesenteric prosthetic bypass in cases of acute mesenteric ischemia, seems to offer a valid and safe approach in order to prevent bowel infarction.KEY WORDS: Acute mesenteric ischemia Angioplasty, Bypass, stent,Thrombolysis.PMID:34668486
CONCLUSION: Dermatologists should suspect CUS in chronic steroid-unresponsive erosive/ulcerative stomatitis. In these cases, to diagnose CUS, the presence of stratified epithelium-specific antinuclear antibodies (SES-ANA) should be investigated through immunofluorescence. Once diagnosed, CUS can be treated with antimalarials, which are an effective treatment contrarily to corticosteroids.PMID:34666534 | DOI:10.1177/20587384211052437
Res Pract Thromb Haemost. 2021 Oct 11;5(7):e12602. doi: 10.1002/rth2.12602. eCollection 2021 Oct.ABSTRACTINTRODUCTION: In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor IX Fc fusion protein concentrate (rFIXFc) prophylaxis. Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are important to evaluate with new treatments.AIMS: To assess HRQoL in people with severe hemophilia B and their experience after switching to rFIXFc prophylaxis.METHODS: Participants completed a Patient Reported Outcomes Burden and Experience (PROBE) questionnaire on initiation and following...
CONCLUSION: Switching from SHL to rFVIIIFc/rFIXFc resulted in short-term meaningful improvement in overall HRQoL and other PROMs in a small proportion. Longitudinal changes on PROMs are affected by ceiling effects and response shift, warranting further studies in instrument optimization in the era of EHL and nonfactor products.PMID:34667922 | PMC:PMC8505988 | DOI:10.1002/rth2.12601
In this study, it was aimed to prospectively evaluate the efficacy, side effects and seroconversion data of inactive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), CoronaVac® (Sinovac, China) vaccine in healthcare workers. A total of 1053 healthcare workers who were initially seronegative (COV2T® SARS-CoV-2 Total Siemens, USA) and vaccinated with inactivated SARS-CoV-2 were included in the study. Quantitative IgG antibodies (ADVIA Centaur® SARS-CoV-2 IgG, Siemens, USA) were investigated 28 days after the first vaccine (n= 939) and the second vaccine (n= 771). In addition, neutralizing antibodies ...